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==========================

Asthma is an immune-mediated process in which an environmental or infectious agent triggers a hypersensitivity immunoglobulin E-mediated allergic response, is triggered by an environmental agent leading to mast cell degranulation, histamine release, and activation of pro-inflammatory cytokines.\[[@ref1]\] Acute exacerbation of asthma is a common reason for Emergency Room visits in children. If initial management fail to control the progression of asthma episode, children may require admission in intensive care unit. Following the initial therapy with inhaled β2 agonists and systemic corticosteroids, a wide array of adjunct medical therapies has been used in the management of status asthmaticus (SA). Unfortunately, the data supporting the use of these adjunct therapies are conflicting, or absent, Extracorporeal membrane oxygenation (ECMO) and inhaled anaesthetic agents have been used with varying success in children with SA not responsive to conventional treatment. Here we report successful use of ECMO and isoflurane in a 6 ½ year male child with refractory SA.

C[ASE]{.smallcaps} R[EPORT]{.smallcaps} {#sec1-2}
=======================================

A 6½-year-old male child presented with a history of cough and cold for 5 days and rapid breathing for the past 5 h. The child was a diagnosed case of mild persistent asthma for the past 3 years and was on intermittent therapy with inhaled steroids and β2 agonists. There was no history of allergy or asthma in other family members. There was no history of hospitalization for acute asthma or any other illness.

The child was taken to a private hospital where, at presentation, he was found to be in respiratory failure with RR 60/min, oxygen saturation (SpO~2~) of 77% with marked chest retractions, and bilateral diminished air entry in lungs. He was started on oxygen inhalation, continuous nebulization with β2 agonist, and intravenous magnesium sulfate. However, the child\'s condition did not improve, and arterial blood gas (ABG) analysis done after 30 min of treatment revealed pH 7.1, PCO~2~ 90 mmHg, PO~2~ 120 mmHg, and HCO~3~28 mmol/L (partial compensated respiratory acidosis). The child was intubated via orotracheal route with a 5.5-mm size cuffed endotracheal tube and started with pressure-regulated volume control (PRVC) mode. In view of high peak inspiratory pressure (PIP 70 cmH~2~O) required to ventilate, the patient was shifted to our facility on bag and tube ventilation.

On admission, the child had heart rate of 150/min, blood pressure of 130/80 mmHg (more than 99^th^ centile for age, sex, and height), and SpO~2~ 96% on bag and tube ventilation. The child was started on PRVC mode with tidal volume (Vt) 8 ml/kg, frequency 20/min, and FiO~2~ 0.5 positive end-expiratory pressure (PEEP) zero. On these settings, the child had an auto-PEEP of 12 cmH~2~O with PIP of 45 mmHg and transairway pressure of 28 cmH~2~O. ABG analysis revealed pH 6.8, PCO~2~ 184 mmHg, PO~2~115 mmHg, and HCO~3~ 24 mmol/L. Chest radiograph showed bilateral hyperinflated lungs \[[Figure 1](#F1){ref-type="fig"}\]. Aerosol therapy with salbutamol (2.5 mg), ipratropium bromide (250 μg) using in-line nebulization system (Aeroneb Solo, Aerogen Ltd, Galway, Ireland), intravenous methylprednisolone (2 mg/kg), ketamine (1 mg/kg/h), magnesium sulfate (50 mg/kg), and aminophylline (0.9 mg/kg/h) infusions was started. In view of the persistent respiratory acidosis, emergency bedside flexible fiberoptic bronchoscopy was done to clear retained secretions. However, with pH remaining \<7 and PCO~2~ above 130 mmHg, the child was initiated on venovenous ECMO after 8 h of admission. The left femoral vein and the right internal jugular vein were cannulated using 17 Fr and 21 Fr Biomedicus (Medtronic, Grand Rapids, Minnesota, USA) ECMO cannulas by the pediatric cardiothoracic team \[[Figure 2](#F2){ref-type="fig"}\]. The patient was kept at 100% flow rate according to body surface area with FiO~2~ 0.4 and sweep gas flow of 1 L/min. The ABG normalized after 40 min of starting ECMO (pH 7.43, PCO~2~ 38.2 mmHg, PO~2~ 150 mmHg, and HCO~3~ 25.2 mmol/L).

![Chest X-ray at admission](IJCCM-22-749-g001){#F1}

![X-ray showing extracorporeal membrane oxygenation cannulas *in situ*](IJCCM-22-749-g002){#F2}

While on ECMO support, resting lung ventilation was continued with volume-controlled mode (frequency 15/min, Vt 6 ml/kg, FiO~2~ 0.4, and PEEP zero). Nebulization with β-agonist and intravenous ketamine infusion were continued. His cerebral oxygenation was monitored by near-infrared spectroscopy with values maintained around 60%--70%. He continued to have severe bronchospasm with transairway pressures of around 35 cmH~2~O and auto-PEEP of 10 cmH~2~O. The child could not be weaned off even after 36 h of institution of ECMO, so was started on inhalation anesthetic isoflurane. Isoflurane was given by a Drager Primus ventilator (MIBII PROTO CONV-LS) to maintain end-expiratory concentration of 1.2%. To prevent exposure of gas to other patients and health-care professionals, isoflurane was given in a special isolation room. Bronchospasm improved within 8 h of starting isoflurane, auto-PEEP decreased to 2 cmH~2~O, transairway pressure decreased to 10 cmH~2~O \[[Figure 3](#F3){ref-type="fig"}\], and air entry in both lungs also improved. He developed hypotension requiring norepinephrine infusion (0.05 μg/kg/min). The child was successfully weaned off ECMO 12 h after starting isoflurane. Isoflurane was also tapered to 0.3% and subsequently stopped after 6 h of ECMO discontinuation. He was extubated on day 6 of admission and discharged from the hospital on inhaled corticosteroids and β 2 agonists on day 10 of hospitalization with no neurological sequelae.
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========================

Asthma is an inflammatory disorder of the airways characterized by airway hyperactivity with bronchospasm, mucosal swelling, and mucus production. SA, also known as acute severe asthma, is a condition of progressively worsening bronchospasm and respiratory dysfunction due to asthma, which is unresponsive to standard conventional therapy and may progress to respiratory failure and the need for mechanical ventilation.\[[@ref2]\] Asthma is a serious public health problem, especially in children. The World Health Organization estimates that \~300 million individuals worldwide suffer from asthma. A further increase in \~400 million is expected by 2025 owing in part to increasing industrialization and pollution in urban areas.\[[@ref3]\] Children are at greater risk with 9.6% compared to 7.7% adults.\[[@ref4]\]

β2 agonists and steroids are the mainstay of treatment causing bronchodilation and anti-inflammatory effects.\[[@ref5]\] Other available adjunct therapies including anticholinergics, magnesium sulfate, methylxanthines, ketamine, and heliox have been utilized with varying results.\[[@ref6]\]

In situations of refractory SA not responding to adjunctive therapies, inhaled anesthetic gases such as isoflurane, halothane, and sevoflurane are alternatives to enhance bronchodilation\[[@ref7]\] \[[Figure 4](#F4){ref-type="fig"}\]. There are several proposed mechanisms of action for inhaled anesthetic gases including beta-adrenergic receptor activation, direct bronchial smooth muscle relaxation by inhibition of acetylcholine and histamine, and hindrance of hypocapnic bronchoconstriction.\[[@ref8]\] Isoflurane and sevoflurane are most commonly used, as halothane may cause severe hepatotoxicity, particularly with prolonged use. The most common adverse effect of these gases is vasodilation resulting in hypotension. In our patient, hypotension occurred with isoflurane, which was managed with norepinephrine. Turner *et al*.\[[@ref9]\] used isoflurane in 31 children over 15 years and reported improvement in pH and PCO~2~ within 4 h of initiation. Inhaled anesthetics are usually used as a rescue therapy in patients of SA due to the high cost and potential for adverse effects. Using inhaled anesthetics outside of the operating room remains challenging as it requires specialized equipment to prevent release of the active gas into the environment and resulting in unintentional exposure to health-care professionals and other patients.\[[@ref10]\]

![Flowchart showing the use of advanced therapies in case of status asthmaticus](IJCCM-22-749-g004){#F4}

When the clinical goals of treatment of SA are not achieved using the appropriate invasive ventilation strategy and intensive medical treatment, ECMO is a modality that may be considered to support gas exchange\[[@ref11]\] \[[Figure 4](#F4){ref-type="fig"}\]. Venovenous ECMO is generally the preferred approach for patients with asthma requiring ECMO.\[[@ref12]\]

Multiple case reports describe successful use of ECMO for refractory SA. Hebbar *et al*.\[[@ref13]\] reported the use of ECMO in 13 children for refractory SA from 1986 to 2007. All patients received aggressive use of medical and anesthetic therapies for SA before initiation of ECMO with a median PaCO~2~ of 130 mmHg (range 102--186 mmHg) and blood pH 6.89 (range 6.75--7.03). Venovenous ECMO was used in 12 patients while venoarterial ECMO was used in one patient. Median time spent on ECMO was 95 h (range 42--395 h). One patient developed pulmonary hemorrhage and pneumothorax occurred in 2 of 13 (15%). All 13 children survived without neurological sequelae.

Inhaled anesthetics such as isoflurane can be used in life-threatening SA not responding to conventional treatment before instituting ECMO. However, in certain emergency circumstances like in our patient who had blood pH 6.8 and PCO~2~184 mmHg which were incompatible with life, instituting early ECMO can be lifesaving as anesthetic gases may take up to 12 h for therapeutic response.\[[@ref11]\]

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

When some patients of severe asthma failed to respond with conventional treatment, inhaled anesthetics such as isoflurane and ECMO can be lifesaving.
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